IN THE past decade great interest in the problems of cerebral vascular disease has developed. Increasing numbers of centers throughout the country have gained experience in the therapy of strokes, some of which offers considerable hope for the future.1 2 It is fitting at the close of this decade to review and assess what has been accomplished and ask what may we expect in the future.
Certain gaps in knowledge as well as definite variables are immediately obvious. Knowledge regarding the natural history of strokes is inadequate to assess fully the value of the therapeutic methods that have been advocated. In addition, the course of a stroke can be so variable from patient to patient that a large number of patients must be studied before any one given measure can be truly validated. All of us have seen many patients with stroke who appeared to be seriously ill at onset and who walked out of the hospital some weeks later, without "active" intervention on the part of the physician. Any disease with so inconsistant a picture must be most carefully investigated before final answers can be given.
It would appear that the attending physician's attitude toward his patient with stroke may play an imporant role in affecting the outcome. In a study of large numbers of patients with strokes, Nielsen3 found that the mortality rate could be reduced from 44 to 31 per cent merely by improving the nature of the general medical care these patients received. In cerebral thrombosis the mortality rate was reduced from 30.2 to 24 per cent. Thus, one must adhere to the following precepts. One cannot be certain of the prognosis at onset. Coma, while carrying serious implications, need not end in death or serious residual impairment. Therefore, all patients with strokes should be made ambulatory and exercised as soon as possible. Maintenance of an adequate cardiac output must be assured. Close attention must be paid to insure adequate pulmonary ventilation. Dehydration must be avoided. Hypoglycemia should never occur and polycythemia must be corrected as rapidly as possible.
Unfortunately, even with the most expert medical and nursing care, there is an irreducible minimum beyond which conservative therapy cannot go, and for this reason more active intervention has been attempted. 3. If one should misdiagnose a small intracerebral hemorrhage as a cerebral thrombosis and initiate anticoagulant therapy, one obviously will worsen the situation. This would seem inevitable if a large enough group of patients is treated.
THERAPY OF CEREBRAL VASCULAR DISEASE
In addition, the raising of a prothrombin time above normal has risks inherent in the procedure itself. Several authors have now reported fatal cerebral hemorrhages in the course of anticoagulant therapy in the acute phase of cerebral thrombosis.2628 The protocols of these patients reveal that many of these complications have occurred in association with a prothrombin time well beyond the accepted therapeutic range. This does not absolve anticoagulant therapy, however, for this may occur with the best of laboratory control. The thromboplastin used by the authors reporting severe hemorrhagic complications has been a brain thromboplastin. Our group believes that this type of thromboplastin is not sufficiently sensitive for this type of work. In addition, our group believes that a dilution of plasma to 12.5 per cent is most helpful in detecting early excess in action on prothrombin activity before the undilute specimen rises into the dangerous area. 29 It is our opinion that every patient should have a spinal fluid examination prior to the institution of anticoagulants for a stroke. Furthermore, we believe that to use anticoagulants Circulation, Volume XXIII, March 1961 in the presence of severe hypertension is to court disaster.
In our controlled study we have not as yet had the ill fortune of a hemorrhagic complication resulting in death either in the acute phase or on long-term therapy. We hope that we can continue to avoid such a tragedy.
4. It is generally agreed that anticoagulant therapy is of no definite value if used after a complete lesion has occurred.'0' 17 In a slowly advancing stroke both Fisher10 and Carter'7 report a definite benefit gained by the use of anticoagulants and this also has been our experience. On the other hand, others have reported anticoagulants to be of no benefit even in this type of stroke. 26 Here again it is hoped that the results of the Cooperative Study may be enlightening.
Anticoagulants have definitely been shown to reduce the incidence of extracerebral thrombosis if used during the acute phase of a stroke. In one large series the incidence has been reduced from 37 to 3 per cent. 30 It also has been the experience of our study group that this is true although at present the number of patients is not large enough to make definite statements.
Thus, one must balance the dangers of the use of anticoagulants against the benefits one hopes to gain. It would seem that at this point the answer is not available and one should avoid advocating the routine use of anticoagulants in the acute phase of a cerebral thrombosis. If the indivdual physician does use anticoagulants, he must carefully select his patients, realizing that this therapy is still in the early stages of development and that far more must be learned before all of the indications and contraindications are universally accepted. Figure 2 Incidence of thromboembolic complications in untreated and treated patients. suited in failure. 13 31, 32 The successful areas approached have been the carotid arteries, especially at the bifurcation, and the vertebral arteries. Well-controlled long-term studies of the value of surgery for these conditions are needed.
E. Fibrinolytic Agents
There are no large studies of the use of these agents in patients with strokes. It may well be that these agents will prove most efficacious in treatment of transient attacks or a slowly progressive stroke, the logic of such thinking being self-evident. It is hoped that a group that is planning to apply its resources to testing these agents will perform a controlled study of the effects of these drugs. Figure 3 Mortality rate in untreated and treated patients.
In another study, the greatest cause of death was again disease of the vessels of the brain and heart.34 In yet another study of 65 patients with thrombosis of the carotidmiddle cerebral tree, 34 per cent were dead of recurrent stroke in 2 years. 35 Thus, one would use anticoagulants in an attempt to reduce the incidence of recurrent thrombosis.
Is there a risk to long-term anticoagulant therapy. In our study there has been a 20 per cent incidence of nonfatal hemorrhagic complications, some of which were definitely serious, with one patient experiencing a subarachnoid hemorrhage ( fig. 1) .
In other studies of the long-term use of anticoagulant drugs in the therapy of coronary artery disease bleeding complications have occurred with a similar incidence.36 In addition, fatal intracerebral hemorrhage has occurred in 3 per cent of patients treated.37
What has been the gain reported? McDevitt and associates38 recently described their experience with a small group of patients who were allowed to serve as their own controls during periods when anticoagulant therapy was discontinued. Of 28 patients, 21 patients experienced a recurrence while off anticoagulant therapy, whereas 8 experienced a recurrence while on anticoagulant therapy.
In our controlled study the number of pa- tients is not large enough to attain any degree of significance (148 patients followed for a maximum period of 33 months). However, there has been a reduction in the incidence of thromboembolism (20 versus 8 per cent) and in the number of deaths attributable to recurrent thromboembolism (38 versus 9 per cent). In addition some of the complications in the "anticoagulant group" occurred after therapy had been discontinued ( figs. 2 and 3) . Thus, the results are suggestive of benefit to be derived from long-term therapy.
A last word about one of the problems of long-term anticoagulant therapy. The charts of a group of patients who had received anticoagulant therapy for 12 months or more were reviewed ( fig. 4) The value of anticoagulants in the acute phase of cerebral thrombosis and in longterm postinfarction therapy is not clear as yet. The role of anticoagulant drugs in treatment of cerebral embolism seems well established. It may be wise to delay institution of these drugs for 24 to 36 hours after the acute stroke. Surgical procedures give promise of value in certain well-defined syndromes. The patient with cerebral hemorrhage remains a formidable therapeutic problem.
